Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0000102909-25-000035·Avalo Therapeutics, Inc.
Schedule 13G ownership disclosure
Avalo Therapeutics, Inc.
Common Stock · CUSIP: 05338F306
Event date: 2025-09-30
- Filing-level shares
- 692,637
- Percent of class
- 5.26%
- The Vanguard Group
Shares: 692,637 · Class: 5.26%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000102909-25-000035
- Form type
- SCHEDULE 13G
- Filer
- Avalo Therapeutics, Inc.
- CIK
- CIK 1534120
- Filed
- Oct 30, 2025
- Reporting period
- Sep 30, 2025
- Description
- Schedule 13G beneficial ownership